These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35286322)

  • 1. The impact of rifaximin on inflammation and metabolism in alcoholic hepatitis: A randomized clinical trial.
    Kimer N; Meldgaard M; Hamberg O; Kronborg TM; Lund AM; Møller HJ; Bendtsen F; Ytting H
    PLoS One; 2022; 17(3):e0264278. PubMed ID: 35286322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA-AH).
    Jiménez C; Ventura-Cots M; Sala M; Calafat M; Garcia-Retortillo M; Cirera I; Cañete N; Soriano G; Poca M; Simón-Talero M; Altamirano J; Lucey M; Garcia-Tsao G; Brown RS; Schwabe RF; Verna EC; Schnabl B; Bosques-Padilla F; Mathurin P; Caballería J; Louvet A; Shawcross DL; Abraldes JG; Genescà J; Bataller R; Vargas V
    Liver Int; 2022 May; 42(5):1109-1120. PubMed ID: 35220659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microbiome as a potential diagnostic and predictive biomarker in severe alcoholic hepatitis.
    Kim SS; Eun JW; Cho HJ; Song DS; Kim CW; Kim YS; Lee SW; Kim YK; Yang J; Choi J; Yim HJ; Cheong JY
    Aliment Pharmacol Ther; 2021 Feb; 53(4):540-551. PubMed ID: 33264437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No Effect in Alcoholic Hepatitis of Gut-Selective, Broad-Spectrum Antibiotics on Bacterial Translocation or Hepatic and Systemic Inflammation.
    Støy S; Laursen TL; Eriksen LL; Grønbæk H; Vilstrup H; Sandahl TD
    Clin Transl Gastroenterol; 2021 Jan; 12(2):e00306. PubMed ID: 33566559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifaximin Reduces Markers of Inflammation and Bacterial 16S rRNA in Zambian Adults with Hepatosplenic Schistosomiasis: A Randomized Control Trial.
    Sinkala E; Zyambo K; Besa E; Kaonga P; Nsokolo B; Kayamba V; Vinikoor M; Zulu R; Bwalya M; Foster GR; Kelly P
    Am J Trop Med Hyg; 2018 Apr; 98(4):1152-1158. PubMed ID: 29436337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot Study.
    Lim YL; Kim MY; Jang YO; Baik SK; Kwon SO
    Gut Liver; 2017 Sep; 11(5):702-710. PubMed ID: 28651304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Use of Rifaximin in Patients With Cirrhosis.
    Caraceni P; Vargas V; Solà E; Alessandria C; de Wit K; Trebicka J; Angeli P; Mookerjee RP; Durand F; Pose E; Krag A; Bajaj JS; Beuers U; Ginès P;
    Hepatology; 2021 Sep; 74(3):1660-1673. PubMed ID: 33421158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy: New hope for alcoholic hepatitis?
    Gao B; Shah VH
    Clin Res Hepatol Gastroenterol; 2015 Sep; 39 Suppl 1(Suppl 1):S7-S11. PubMed ID: 26193867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial.
    Kimer N; Pedersen JS; Tavenier J; Christensen JE; Busk TM; Hobolth L; Krag A; Al-Soud WA; Mortensen MS; Sørensen SJ; Møller S; Bendtsen F;
    J Gastroenterol Hepatol; 2018 Jan; 33(1):307-314. PubMed ID: 28671712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rifaximin prevents ethanol-induced liver injury in obese KK-A
    Kitagawa R; Kon K; Uchiyama A; Arai K; Yamashina S; Kuwahara-Arai K; Kirikae T; Ueno T; Ikejima K
    Am J Physiol Gastrointest Liver Physiol; 2019 Nov; 317(5):G707-G715. PubMed ID: 31509430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: study protocol for a randomized controlled trial.
    Madsen BS; Trebicka J; Thiele M; Israelsen M; Arumugan M; Havelund T; Krag A
    Trials; 2018 Feb; 19(1):143. PubMed ID: 29482588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Pose E; Napoleone L; Amin A; Campion D; Jimenez C; Piano S; Roux O; Uschner FE; de Wit K; Zaccherini G; Alessandria C; Angeli P; Bernardi M; Beuers U; Caraceni P; Durand F; Mookerjee RP; Trebicka J; Vargas V; Andrade RJ; Carol M; Pich J; Ferrero J; Domenech G; Llopis M; Torres F; Kamath PS; Abraldes JG; Solà E; Ginès P
    Lancet Gastroenterol Hepatol; 2020 Jan; 5(1):31-41. PubMed ID: 31607677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood Biomarkers of Intestinal Epithelium Damage Regenerating Islet-derived Protein 3α and Trefoil Factor 3 Are Persistently Elevated in Patients with Alcoholic Hepatitis.
    Yang J; Syed F; Xia Y; Sanyal AJ; Shah VH; Chalasani N; Zheng X; Yu Q; Lou Y; Li W
    Alcohol Clin Exp Res; 2021 Apr; 45(4):720-731. PubMed ID: 33587293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Granulocyte Colony-Stimulating Factor and N-Acetylcysteine Therapies in Patients With Severe Alcoholic Hepatitis.
    Singh V; Keisham A; Bhalla A; Sharma N; Agarwal R; Sharma R; Singh A
    Clin Gastroenterol Hepatol; 2018 Oct; 16(10):1650-1656.e2. PubMed ID: 29391265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating concentrations of interleukin-18, interleukin-18 binding protein, and gamma interferon in patients with alcoholic hepatitis.
    Spahr L; Garcia I; Bresson-Hadni S; Rubbia-Brandt L; Guler R; Olleros M; Chvatchko Y; Hadengue A
    Liver Int; 2004 Dec; 24(6):582-7. PubMed ID: 15566508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: an open label trial.
    Sharma P; Kumar A; Sharma BC; Sarin SK
    J Hepatol; 2009 Mar; 50(3):584-91. PubMed ID: 19155081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editorial: microbiome modulation by rifaximin in severe alcoholic hepatitis.
    Youn GS; Suk KT
    Aliment Pharmacol Ther; 2021 Feb; 53(4):561-562. PubMed ID: 33616993
    [No Abstract]   [Full Text] [Related]  

  • 18. Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis.
    Dominguez M; Miquel R; Colmenero J; Moreno M; García-Pagán JC; Bosch J; Arroyo V; Ginès P; Caballería J; Bataller R
    Gastroenterology; 2009 May; 136(5):1639-50. PubMed ID: 19208360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma endotoxin and serum cytokine levels in patients with alcoholic hepatitis: relation to severity of liver disturbance.
    Fujimoto M; Uemura M; Nakatani Y; Tsujita S; Hoppo K; Tamagawa T; Kitano H; Kikukawa M; Ann T; Ishii Y; Kojima H; Sakurai S; Tanaka R; Namisaki T; Noguchi R; Higashino T; Kikuchi E; Nishimura K; Takaya A; Fukui H
    Alcohol Clin Exp Res; 2000 Apr; 24(4 Suppl):48S-54S. PubMed ID: 10803780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers of Macrophage Activation and Immune Danger Signals Predict Clinical Outcomes in Alcoholic Hepatitis.
    Saha B; Tornai D; Kodys K; Adejumo A; Lowe P; McClain C; Mitchell M; McCullough A; Dasarathy S; Kroll-Desrosiers A; Barton B; Radaeva S; Szabo G
    Hepatology; 2019 Oct; 70(4):1134-1149. PubMed ID: 30891779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.